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Background. Direct-acting antivirals (DAA) allow effective and safe eradication of hepatitis C virus (HCV) in most patients. 
There are limited data on the long-term effects of all-oral, interferon-free DAA combination therapies in kidney transplant (KT) 
patients infected with HCV. Here we evaluated the long-term tolerability, efficacy, and safety of DAA combination therapies 
in KT patients with chronic HCV infection. Methods. Clinical data from KT patients treated with DAA were collected 
before, during, and after the treatment, including viral response, immunosuppression regimens, and kidney and liver function. 
Results. Patients (N = 226) were mostly male (65.9%) aged 56.1 ± 10.9 years, with a median time from KT to initiation 
of DAA therapy of 12.7 years and HCV genotype 1b (64.6%). Most patients were treated with sofosbuvir-based therapies. 
Rapid virological response at 1 month was achieved by 89.4% of the patients and sustained virological response by week 12 
by 98.1%. Liver function improved significantly after DAA treatment. Tacrolimus dosage increased 37% from the beginning 
of treatment (2.5 ± 1.7 mg/d) to 1 year after the start of DAA treatment (3.4 ± 1.9 mg/d, P < 0.001). Median follow-up was 
37.0 months (interquartile range, 28.4–41.9) and death-censored graft survival was 91.1%. Adverse events resulting from 
DAA treatment, especially anemia, were reported for 31.0% of the patients. Conclusions. Chronic HCV infection can be 
treated efficiently and safely with DAA therapy in KT patients. Most patients retained stable kidney function and improved liver 
function. Tacrolimus dose had to be increased in most patients, potentially as a result of better liver function.
(Transplantation Direct 2019;5: e510; doi: 10.1097/TXD.0000000000000954. Published online 18 November, 2019.)
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Kidney transplant (KT) recipients who are hepatitis C virus (HCV)-positive have an increased risk of other infec-
tions, new-onset diabetes mellitus, cardiovascular diseases, 
liver fibrosis, graft loss, and mortality.1,2 The immunosuppres-
sive regimen required after transplantation can promote viral 
replication, leading to progression of liver disease or reactiva-
tion of HCV infection and exacerbation of hepatitis. Active 
viral replication at transplantation is an independent risk fac-
tor for graft failure in this type of patients.3 However, kidney 
transplantation is still recommended, as mortality is higher if 
continuing on maintenance hemodialysis.4
Antiviral therapy based on interferon (IFN) or ribavirin is 
not recommended in patients with impaired renal function 
because both drugs are eliminated by the kidneys and reduced 
doses are required. In KT patients, the therapies based on IFN 
have been associated with poor efficacy, low tolerability, and 
increased risk of graft rejection.2,5
In recent years, the introduction of oral antiviral drugs that 
directly inhibit viral proteins have revolutionized the treat-
ment of HCV-positive patients.6 The first IFN-free direct-
acting antiviral (DAA) therapy implemented was sofosbuvir, 
an inhibitor of the viral RNA polymerase, approved by the 
US Food and Drug Administration in December 2013.7 
Currently, there are 4 major classes of approved DAA drugs 
targeting 3 different nonstructural viral proteins: NS3/4A pro-
tease inhibitors (eg, simeprevir, paritaprevir, grazoprevir, gle-
caprevir, voxilaprevir); NS5A replication complex inhibitors 
(eg, ledipasvir, ombitasvir, elbasvir, daclatasvir, velpatasvir, 
pibrentasvir); non-nucleoside NS5B polymerase inhibitors 
(eg, dasabuvir); and nucleoside NS5B polymerase inhibitors 
(sofosbuvir). Used in combinations and with/without riba-
virin, they can often lead to sustained virological responses 
(SVR) >90% in 12 weeks or less among patients that are treat-
ment naïve,8 compared with curation rates of 34% in 24–48 
weeks with previous treatments.9 Compared with IFN-based 
treatments, the safety of oral DAA therapies has been well 
tested on patients with renal dysfunction. Recently devel-
oped pangenotypic DAA combinations, such as glecaprevir/
pibrentasvir, have emerged as major advances for patients 
with severe kidney impairment.10,11 However, the long-term 
treatment effects are still poorly known,12 as drug–drug inter-
actions are a possibility in patients compromised by other 
diseases.
In KT patients with concomitant HCV infection, the ben-
efits of DAA therapies include a reduced risk of graft rejec-
tion compared with IFN-based therapies, as well as improved 
liver function. HCV eradication with DAA treatments has 
been shown to improve significantly the quality of life of KT 
patients.13 Another advantage of DAA treatments is that more 
HCV-infected kidneys will be available for transplants, thus 
reducing waiting lists and time on hemodialysis for affected 
patients.14-16 It could also be expected that there will be a 
reduction in the number of severe renal impairment patients 
that will require a dual kidney and liver transplant.
There is a growing body of evidence regarding the efficacy 
and safety of DAAs in KT recipients.17-25 The review of the 
available data indicates that DAA therapies can cure HCV 
in most KT patients (>98%) with no major safety-associated 
concerns.17,26 They also highlighted the need for careful moni-
toring of immunosuppressive drug levels shortly after DAA 
treatment initiation, as well as the need for close collabora-
tion between hepatologists and transplantation nephrologists. 
Although large cohort studies will be needed to assess the 
clinical and long-term benefits of DAAs in the KT patient 
population, the European Association for the Study of the 
Liver and the Spanish Association of the Liver and the Kidney 
encourage the use of DAA therapies for the treatment of HCV 
infection in chronic kidney disease.11,27
In this observational, prospective, multicenter study, we 
present our results of 226 cases of HCV-infected KT recipi-
ents treated with DAA. This analysis is an extension of a pre-
vious preliminary report of 119 cases.18 Our main objective 
here was to investigate the long-term tolerability, efficacy, and 
safety of a variety of IFN-free DAA combination therapies 
currently used in Spanish reference hospitals.
MATERIALS AND METHODS
This observational, multicentric, prospective study included 
KT patients from 19 reference hospitals throughout Spain 
from March 2013 to May 2017. All patients were ≥18 years 
old, HCV-positive at the time of transplant, and received 
DAA therapy. The study protocol was approved by the Ethics 
Committee of the Virgen del Rocío Hospital, Seville (Spain). 
All eligible patients provided written informed consent before 
undergoing study-related procedures. The trial was conducted 
in accordance with the Declaration of Helsinki.28
Patients were followed prospectively and clinical, virologi-
cal, and laboratory data were collected at a basal visit before 
the treatment started, 1 month after treatment start (before 
its finalization), and 1 month, 3 months, 1 year after the 
treatment ended. All data collected by the investigators were 
placed into a single database for further analysis.
Efficacy of the therapy was defined as the SVR after 30, 90 
(SVR-12), and 365 days of treatment. Safety of the therapy 
was assessed as a function of renal function (creatinine, esti-
mated glomerular filtration rate [eGFR]), proteinuria, immu-
nosuppression levels, and changes in the diabetes treatment 
for diabetic patients (as judged by the investigator). Risk of 
recurrence was also evaluated. Fibrosis stage was evaluated by 
transient elastography (FibroScan). Compliance with antiviral 
therapy and rate of adverse events were monitored through 
the treatment duration and follow-up by review of clinical 
charts by the clinicians at each of the hospitals.
Statistical analysis was performed using the SPSS 22.0 sta-
tistical software for Windows. All values were calculated from 
the number of valid cases (N). Quantitative variables were 
described as means and standard deviations or as medians 
with interquartile ranges (IQR). Categorical variables were 
presented as lists of frequencies and proportions. Comparisons 
of numerical variables were performed using the paired t test 
or the Wilcoxon test.
RESULTS
Patient Population
This study included 226 KT recipients with chronic HCV 
infection. The basal demographic and clinical characteris-
tics of the patients are shown in Table 1. Most patients were 
male (65.9%) and the mean age was 56.1 ± 10.9 years, with 
a median time from KT to initiation of DAA therapy of 12.7 
years (IQR, 6.3–21.9). The median time of follow-up after 
initiation of antiviral therapy was 37.0 months (IQR, 28.4–
41.9). Nineteen patients were recipients of a combined liver 
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and KT and 4 had simultaneous pancreatic and KTs. Seventy-
four patients (32.7%) presented diabetes, which was treated 
with oral antidiabetics (8.4%), insulin (19.5%), or a combi-
nation of both (2.7%).
Baseline viral genotypes are shown in Table 1. Genotype 
1b was the most frequent (146 patients, 64.6%). Fifty-seven 
patients (25.2%) had received previous HCV treatment. 
Further, 8 and 6 patients tested positive for hepatitis B virus 
and HIV, respectively. Thirty-five patients (15.5%) presented 
portal hypertension and 5 patients (2.2%) had hepatocellular 
carcinoma.
Antiviral Treatments and Virological Response
A total of 11 different antiviral regimens were prescribed 
in our cohort study (Table 2). More than half of the patients 
were treated with the combination of sofosbuvir and ledipas-
vir (118 patients, 52.2%). The combination of sofosbuvir and 
ribavirin, with or without other DAA, was used in 38 patients 
(16.8%). The median treatment duration was 12.3 weeks 
(IQR, 11.9–15.7 wk). Of the 207 patients who completed the 
treatment, 185 (89.4%) patients achieved rapid virological 
response after 1 month of treatment, with undetectable viral 
load. After completion of the 12-week DAA treatment, 203 
patients (98.1%) achieved SVR-12. One year after the start of 
treatment, there were no cases recorded of infection relapse or 
retreatment with antivirals.
There were 12 patients (5.3%) who discontinued treatment; 
half of them had been treated with the combination of ombi-
tasvir, ritonavir, paritaprevir, and dasabuvir. Discontinuation 
was due to pancytopenia in 2 patients, neural toxicity in 3 
patients, hepatic toxicity in 2 patients, and gastrointestinal 
toxicity in 1 patient; in 1 patient, the reason was not regis-
tered and there were 3 deaths: 2 due to sepsis and 1 due to 
acute myocardial infarction. In these cases, the median treat-
ment duration was 3.3 weeks (IQR, 1.9–12.2).
Graft Function and Immunosuppression
Clinical renal and hepatic parameters before and 1 year 
after the start of DAA treatment are shown in Table 3. The 
indicators of kidney function worsened, as eGFR decreased 
significantly (P = 0.003, paired t test). Renal function was not 
significantly different between DAA treatment regimens. All 
indicators of liver function presented very significant improve-
ments (P < 0.001).
All patients were on 1 or more immunosuppressive agents, 
of which tacrolimus was the most frequent (67.7%, Table 1). 
Tacrolimus trough levels were reduced 1 year after the start of 
DAA therapy (7.2 ± 1.9 ng/mL at start versus 6.6 ± 2.3 ng/mL, 
P = 0.041). The total daily dose of tacrolimus significantly 
increased 1 year after the start of the treatment (2.5 ± 1.7 
versus 3.4 ± 1.9 mg/d; P < 0.001).
During the median 37 months of follow-up, the death-
censored graft survival was 96.9% after 1 year, 96.4% after 
2 years, and 91.1% after 37 months. The causes of graft loss 
were interstitial fibrosis plus tubular atrophy in 10 patients, 
chronic humoral rejection in 3 patients, and cryoglobuline-
mia in 3 patients. Patient survival (DAA-treated) was 96.4% 
after 1 year, 95.8% after 2 years, and 89.1% after 37 months. 
Causes of death were cancer (lung and cholangiocarcinoma) 
in 6 patients, cardiovascular events in 6 patients, sepsis in 5 
patients, liver failure due to cirrhosis in 2 patients, and other 
causes in 4 patients.
Adverse Events
A total of 70 patients (31.0%) reported adverse events while 
on DAA treatment (Table 2). The most common adverse event 
was anemia, which was serious in 25 of the cases and highly 
prevalent in patients treated with ribavirin (>60% of patients). 
A decline of kidney function was observed in 17 patients 
(7.5%). Neutropenia and thrombopenia were detected in 
3.1% and 5.3% of patients, respectively. In addition to the 
adverse events shown in Table  2, there were also reported 
cases of asthenia (4 patients), nausea and vomiting (3 patients), 
headache (3 patients), skin rash (2 patients), tacrolimus toxic-
ity (2 patients), and hepatotoxicity (2 patients). Toxicity due to 
tacrolimus was observed in 2 of the 16 patients treated with 
ombitasvir, ritonavir, paritaprevir, and dasabuvir, but we found 
no other cases of toxicity in any of the other DAA treatments.
DISCUSSION
In this study, we describe the results of the medium to 
long-term treatment of HCV-infected KT recipients with the 
TABLE 1.
Basal demographic and clinical characteristics, N = 226
Age (y), mean ± SD 56.1 ± 10.9
Gender (male), N (%) 149 (65.9)
Primary cause of kidney disease, N (%)
 Glomerulonephritis 60 (26.5)
 Interstitial 35 (15.5)
 Polycystic kidney disease 20 (8.8)
 Diabetic nephropathy 16 (7.1)
 Systemic disease 7 (3.1)
 Unknown/other 78 (38.9)
Previous transplants, N (%)
 0 150 (66.4)
 1 64 (28.3)
 2–3 11 (5.3)
Immunosuppressive treatment, N (%)a
 Tacrolimus 153 (67.7)
 Mycophenolate 151 (66.8)
 Steroids 161 (71.2)
 Cyclosporine 37 (16.4)
 Azathioprine 12 (5.3)
 Everolimus 15 (6.6)
 Rapamycin 11 (4.9)
HCV genotype, N (%)
 1 1 (0.4)
 1a 34 (15.0)
 1a/1b 1 (0.4)
 1b 146 (64.6)
 2 12 (5.3)
 3 11 (4.9)
 3a 5 (2.2)
 4 11 (4.9)
 6 1 (0.4)
 Unknown/no data 4 (1.7)
Fibrosis, N (%)  
 0–2 104 (46.1)
 3–5 66 (29.2)
 Unknown/no data 56 (24.8)
Patients could have multiple treatments.
HCV, hepatitis C virus; SD, standard deviation.
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recently developed DAA therapies. The virological response 
was very high (98.1% achieved SVR-12) and, after a median 
follow-up of 26.6 months, patient and graft survival were 
>95%. SVR was similar in double liver/kidney or pancreas/KT 
patients, suggesting that immunosuppression did not affect 
the effectiveness of the therapy. Additionally, we observed 
no post-treatment relapses. One year after the antiviral treat-
ment, hepatic function experienced significant improvements 
in most patients.
The SVR-12 observed in our study is comparable to that 
found in other series, which range from 91% to 100% in this 
patient population.20-22,25,29-31 In our study, some patients devel-
oped mild allograft dysfunction and some patients required 
immunosuppression dose adjustment. One year after initia-
tion of DAA treatment, our study showed that tacrolimus dose 
had to be significantly increased to maintain levels within tar-
get ranges. Immunosuppressive dose adjustment in KT or liver 
transplant recipients receiving DAA has been observed previ-
ously.32-34 It has been suggested that drug–drug interactions 
could develop during DAA therapy, as the NS3/4A protease 
inhibitors are degraded in the liver by cytochrome P450, which 
also metabolizes calcineurin inhibitors. However, in our study, 
only 50 patients (22%) received NS3/4A protease inhibitors 
simeprevir, paritaprevir, or grazoprevir. Another possibility is 
that enhanced liver function is the result of improved metab-
olism of the calcineurin inhibitors as a consequence of the 
DAA treatment. Proinflammatory cytokines may inhibit 
cytochrome P450 enzymes during HCV infection, which are 
then restored to normal function after virus clearance.32 This 
apparent DAA-induced reversibility of liver function could be 
more pronounced in KT patients with lower degrees of fibro-
sis compared with those with severe fibrosis or cirrhosis.33 In 
the non-KT population, the biochemical parameters of liver 
function improve shortly after DAA therapy,35 with regression 
of fibrosis, normalization of portal hypertension and liver 
stiffness, and increase in skeletal muscle mass.36-38
Independent of intervention, some functional deterioration 
is expected in KT patients followed in time, as reflected in 
their clinical parameters. In our study, we could not determine 
if there had been a prior decline in renal function, or even an 
improvement, as no data were available before DAA treat-
ment. The observed variation in renal function was not clini-
cally significant and the survival of the transplanted kidney 
censored for death, 91.1% after a median follow-up of 37.0 
months, was high. Likely the elimination of the virus sup-
presses or limits its negative impact, improving the survival of 
the patient and the transplanted organ until it equals or nears 
that of the negative HCV receptors. Our study and others 
TABLE 2.
DAA treatments and adverse events, N (%)
Treatment Frequencya Discontinuedb
Adverse eventsb,c
Anemia Kidney function decline Neutropenia Thrombopenia
Sofosbuvir, ledipasvir 118 (52.2) 2 (1.7) 4 (3.4) 9 (7.6) 0 3 (2.5)
Sofosbuvir, simeprevir 23 (10.2) 1 (4.3) 0 2 (8.7) 1 (4.3) 1 (4.3)
Sofosbuvir, daclatasvir 21 (9.3) 1 (4.8) 1 (4.8) 1 (4.8) 0 0
Sofosbuvir, ribavirin, ledipasvir 21 (9.3) 2 (9.5) 13 (61.9) 0 4 (19.0) 5 (23.8)
Ombitasvir, ritonavir, paritaprevir, dasabuvir 16 (7.1) 6 (37.5) 6 (37.5) 3 (18.8) 1 (6.3) 2 (12.5)
Sofosbuvir, rivabirin 8 (3.5) 0 6 (75.0) 0 1 (12.5) 0
Grazoprevir, elbasvir 7 (3.1) 0 0 0 0 0
Sofosbuvir, ribavirin, daclatasvir 5 (2.2) 0 3 (60.0) 1 (20.0) 0 1 (20.0)
Sofosbuvir, ribavirin, simeprevir 4 (1.8) 0 1 (25.0) 0 0 0
Sofosbuvir 2 (0.9) 0 0 0 0 0
Simeprevir, daclatasvir, ribavirin 1 (0.4) 0 0 1 (100.0) 0 0
Totala 226 (100.0) 12 (5.3) 34 (15.0) 17 (7.5) 7 (3.1) 12 (5.3)
aPercentages calculated over total number of patients.
bPercentages calculated over patients under this treatment.
cMore than 1 adverse event could occur in the same patient.
DAA, direct-acting antivirals.
TABLE 3.
Clinical parameters of kidney and liver function
N Pretreatment Post-treatmenta Pb
Creatininec (mg/dL) 147 1.36 (0.51) 1.50 (1.02) 0.016
eGFR (CKD-EPI)c (mL/min/1.73 m2) 198 61.40 (21.45) 58.75 (22.30) 0.003
Proteinuriac (mg/24 h) 184 355.18 (538.12) 813.68 (3524.03) 0.586d
GGTe (U/L) 136 60 (34–126) 22 (16–42) <0.001
Total bilirubine (mg/dL) 136 0.61 (0.50–0.87) 0.50 (0.40–0.80) <0.001
ALTe (U/L) 136 52.5 (31.3–84.5) 17 (13.0–25.0) <0.001
aIndicated post-treatment values are 1 year after start of direct-acting antiviral therapy.
bPaired t test, unless otherwise stated.
cMean (SD).
dWilcoxon test.
eMedian (interquartile range).
ALT, alanine transaminase; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GGT, gamma glutamyl transferase; SD, standard deviation.
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were not designed to assess the functional evolution of the 
kidney in the same patient before and after treatment (com-
paring the slope of loss of eGFR as a predictor of its long-
term survival). Possibly this issue cannot be resolved directly 
and conclusively, although large registries could be used to 
develop retrospective studies by following large cohorts of 
patients.
DAA therapy was well tolerated, as in previously reported 
series,17-19,21-25 with only 5.3% of the patients discontinu-
ing treatment. Most common adverse event was anemia in 
patients treated with ribavirin, a well-known effect of this 
antiviral.39 The highest proportion of discontinuation due to 
DAA adverse effects was seen for patients taking the com-
bination of ombitasvir, ritonavir, paritaprevir, and dasabu-
vir (6 patients, 37.5% of all discontinuations). We did not 
register the emergence of serious infections that required 
hospitalization.
Currently, the European Association for the Study of the 
Liver recommends a fixed-dose combination of sofosbuvir 
and ledipasvir (genotypes 1, 4, 5, and 6) without the need 
for immunosuppressant drug dose adjustments in case of 
KT patients with acceptable kidney function.11 However, the 
fixed-dose combination of glecaprevir and pibrentasvir for 12 
weeks, with immunosuppressant drug adjustments as needed, 
is recommended for patients with severe kidney impairment 
(eGFR <30 mL/min/1.73 m2).11 Although current therapeutic 
protocols for KT patients seem highly effective and safe, it is 
likely that novel combination DAA therapies will be devel-
oped in the future for those patients with comorbidities or 
refractory to treatment.
To date, this multicentric observational study of 226 
patients reflecting current clinical practices is the largest of 
its kind in Europe and with the longest follow-up (37 mo). 
However, the study was limited by patient heterogeneity (eg, 
genotypes, degree of fibrosis) and diversity in DAA regimes, 
which prevented comparative and statistically significant 
analysis of effectiveness or safety.
CONCLUSIONS
Our study confirms that HCV infection can be success-
fully and safely treated after kidney transplantation with a 
12-week course of treatment with DAAs. After a median fol-
low-up of 37 months, most patients improved liver function 
and retained clinically stable kidney activity. Patients required 
a significant increase in tacrolimus dose to maintain trough 
levels without changes in other immunosuppressive drugs.
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